NCT06834295View on ClinicalTrials.gov

A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

March 23, 2025

Study Completion Date

March 23, 2025

Conditions
Healthy Males
Interventions
DRUG

Vapendavir

Single oral dose of \[14C\]vapendavir

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
lead

Altesa Biosciences, Inc.

INDUSTRY

NCT06834295 - A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir | Biotech Hunter | Biotech Hunter